Mergers and acquisitions – Page 5
-
-
BusinessRoche offloads majority of rights to lebrikizumab
Deal with Dermira could be worth well over $1 billion
-
BusinessBristol-Myers Squibb bags immunotherapy unicorn
Deal will add to pharma giant’s cancer portfolio
-
BusinessGenesis Energy to buy alkali business from Tronox
Tronox to spend proceeds on Cristal purchase
-
BusinessMitsubishi Tanabe Pharma buys Neuroderm for $1.1 billion
Japanese pharmaceutical giant to acquire Israel’s Neuroderm in record breaking deal
-
BusinessEU to investigate Merck KGaA’s merger with Sigma–Aldrich
Commission says Merck failed to disclose a crucial research project
-
BusinessCelgene and BeiGene agree cancer partnership
Immuno-oncology deal sees firms exchange licensing rights for antibody drugs
-
BusinessJ&J licenses Protagonist’s inflammatory bowel peptide
Potential first-in-class treatment is just about to enter clinical trials
-
BusinessIneos expands North Sea oil and gas operations
Purchase of Danish Dong Energy and BP’s Forties pipeline will feed Grangemouth refinery
-
BusinessHuntsman and Clariant agree merger deal
Uniting Huntsman’s bulk materials with Clariant’s additives gives a more integrated speciality chemicals offering
-
BusinessSeattle Genetics cancels Immunomedics deal
Settlement also resolves disputes with shareholders
-
BusinessPatheon buyout brings Thermo into contract manufacturing
$7.2bn deal expands Thermo Fisher’s laboratory products and services segment
-
BusinessAvantor to buy VWR for $6.4bn
Deal continues trend of consolidation in laboratory supplies sector
-
BusinessMerck KGaA to buy Chematica
Retrosynthesis tool will gain computational muscle and integrate with Sigma–Aldrich catalogue
-
BusinessBP to sell Chinese joint venture stake to Sinopec
Oil giant retains significant investment in China, but is shifting focus
-
BusinessFarmers sue to block Syngenta–ChemChina merger
Planned takeover will decrease competition, leading to higher costs and fewer options for farmers
-
BusinessFresenius to buy Akorn and Merck KGaA’s biosimilars
Deals give Fresenius entry into rapidly growing biological drugs market
-
BusinessHow do chemical firms last hundreds of years?
What distinguishes companies that thrive from others that failed?
-
BusinessEU conditionally approves Dow–DuPont merger
To satisfy competition concerns, DuPont will swap crop protection R&D assets for FMC’s nutrition business
-
BusinessShell shrinks stake in Canadian oil sands
$7.25bn sell-off is part of plan to divest over $30bn in assets to reduce debts